Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Authors :: Regis Peffault de Latour
Alexander Roeth
Austin Kulasekararaj
Phillip Scheinberg
Yasutaka Ueda
Carlos M de Castro
Eros Di Bona
Hubert Schrezenmeier
Saskia MC Langemeijer
Wilma Barcellini
Suzanne Tavitian
Jens Panse
Philippe Schafhausen
Vitor AQ Mauad
Cecile Kerloeguen
Rafael Levitch
Rakesh Kumar
Christine Thorburn
Samopriyo Maitra
Marion Dahlke
Antonio M Risitano
Source :: Blood. 140:LBA-2
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools